Ascendis Pharma A/S (NASDAQ:ASND – Free Report) – Wedbush boosted their Q3 2023 earnings per share (EPS) estimates for Ascendis Pharma A/S in a report issued on Wednesday, September 6th. Wedbush analyst A. Argyrides now expects that the biotechnology company will post earnings per share of ($2.28) for the quarter, up from their prior estimate of ($2.34). Wedbush has a “Outperform” rating and a $192.00 price target on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($9.69) per share. Wedbush also issued estimates for Ascendis Pharma A/S’s Q4 2023 earnings at ($1.83) EPS, FY2023 earnings at ($8.55) EPS, FY2024 earnings at ($3.46) EPS and FY2025 earnings at ($1.24) EPS.
ASND has been the topic of several other research reports. Wells Fargo & Company reduced their price target on shares of Ascendis Pharma A/S from $139.00 to $134.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 6th. Morgan Stanley upped their target price on shares of Ascendis Pharma A/S from $109.00 to $113.00 and gave the company an “equal weight” rating in a research report on Wednesday, September 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $152.00 price objective on shares of Ascendis Pharma A/S in a research report on Thursday. Bank of America increased their price objective on Ascendis Pharma A/S from $107.00 to $113.00 in a research note on Thursday. Finally, StockNews.com cut shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Wednesday, August 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.20.
Ascendis Pharma A/S Trading Down 5.4 %
Shares of ASND stock opened at $97.58 on Monday. Ascendis Pharma A/S has a twelve month low of $64.33 and a twelve month high of $134.52. The stock has a market cap of $5.59 billion, a price-to-earnings ratio of -8.64 and a beta of 0.50. The company’s 50-day moving average price is $92.25 and its 200-day moving average price is $93.16. The company has a current ratio of 3.52, a quick ratio of 3.32 and a debt-to-equity ratio of 7.39.
Institutional Investors Weigh In On Ascendis Pharma A/S
Several large investors have recently modified their holdings of the stock. Envestnet Asset Management Inc. boosted its stake in shares of Ascendis Pharma A/S by 14.4% in the first quarter. Envestnet Asset Management Inc. now owns 2,246 shares of the biotechnology company’s stock valued at $264,000 after buying an additional 282 shares in the last quarter. Rice Hall James & Associates LLC increased its stake in shares of Ascendis Pharma A/S by 35.1% during the 1st quarter. Rice Hall James & Associates LLC now owns 134,900 shares of the biotechnology company’s stock valued at $15,832,000 after acquiring an additional 35,039 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Ascendis Pharma A/S by 20.5% during the 1st quarter. Bank of New York Mellon Corp now owns 289,344 shares of the biotechnology company’s stock worth $33,958,000 after acquiring an additional 49,298 shares during the period. BlackRock Inc. boosted its position in shares of Ascendis Pharma A/S by 25.3% in the first quarter. BlackRock Inc. now owns 401,084 shares of the biotechnology company’s stock worth $47,070,000 after acquiring an additional 80,988 shares during the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in Ascendis Pharma A/S in the first quarter valued at approximately $14,083,000.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia.
Read More
- Five stocks we like better than Ascendis Pharma A/S
- Investing in Construction Stocks
- MarketBeat Week in Review – 9/4 – 9/8
- Space Investment: How to Invest in Space Exploration
- The Best 5 Small Cap AI Companies to Buy Now
- What is a SEC Filing?
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
